Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cytochrome bc1:aa3 oxidase supercomplex is a critical component of the Mycobacterium tuberculosis respiratory chain, responsible for transferring electrons from menaquinol to oxygen and generating the proton motive force required for ATP synthesis (Current Molecular Pharmacology, 2022; PNAS, 2017). It consists of two main parts: the cytochrome bc1 complex (menaquinone:cytochrome c reductase) and the cytochrome aa3 oxidase (cytochrome c oxidase), which form an obligate supercomplex in mycobacteria (Nature Medicine, 2013; eLife, 2021). This supercomplex is a validated therapeutic target, with the QcrB subunit of the bc1 complex being the primary binding site for several novel antitubercular agents, most notably Telacebec (Q203) (Nature Medicine, 2013; Expert Opinion on Investigational Drugs, 2022). Inhibition of this target leads to a rapid collapse of intracellular ATP levels, although the presence of an alternative terminal oxidase, cytochrome bd, can provide respiratory flexibility and limit the bactericidal efficacy of bc1:aa3 inhibitors (PNAS, 2017; EMBO Molecular Medicine, 2020). Consequently, current research explores combining bc1:aa3 inhibitors with other agents to overcome this redundancy and achieve more effective sterilization of M. tuberculosis infections, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains (Antimicrobial Agents and Chemotherapy, 2022). The target's high specificity for mycobacterial enzymes over human mitochondrial homologs minimizes host toxicity, making it a promising focus for the development of shorter, safer treatment regimens for tuberculosis and other mycobacterial diseases like Buruli ulcer and leprosy (NEJM, 2020; Qurient, 2021).
Inhibition of the QcrB subunit (cytochrome b) of the cytochrome bc1 complex, which disrupts the electron transport chain and leads to a rapid depletion of intracellular ATP levels.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome bc1:aa3 oxidase supercomplex (bc1:aa3).